WO2002060932A2 - A serpin in bifidobacteria - Google Patents

A serpin in bifidobacteria Download PDF

Info

Publication number
WO2002060932A2
WO2002060932A2 PCT/EP2002/000956 EP0200956W WO02060932A2 WO 2002060932 A2 WO2002060932 A2 WO 2002060932A2 EP 0200956 W EP0200956 W EP 0200956W WO 02060932 A2 WO02060932 A2 WO 02060932A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
polypeptide
serpin
seq
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/000956
Other languages
French (fr)
Other versions
WO2002060932A3 (en
Inventor
Fabrizio Arigoni
Stéphanie Blum
Michele Delley
Mark Alan Schell
Eduardo Schiffrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Priority to JP2002561500A priority Critical patent/JP4249483B2/en
Priority to AU2002249151A priority patent/AU2002249151A1/en
Priority to EP02718062A priority patent/EP1358332B1/en
Priority to DE60215461T priority patent/DE60215461T2/en
Priority to US10/470,559 priority patent/US7700315B2/en
Priority to CA2436049A priority patent/CA2436049C/en
Publication of WO2002060932A2 publication Critical patent/WO2002060932A2/en
Publication of WO2002060932A3 publication Critical patent/WO2002060932A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C2220/00—Biochemical treatment
    • A23C2220/20—Treatment with microorganisms
    • A23C2220/202—Genetic engineering of microorganisms used in dairy technology
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention pertains to a novel gene of Bifidobacteria and to the polypeptides encoded thereby.
  • the present invention pertains to a gene belonging to the Serpin superfamily and its use in the production of bacterial Serpins.
  • vectors, host cells, and methods for producing bacterial Serpin polynucleotides and/or polypeptides are also provided.
  • Lactic acid bacteria have been utilized for the preservation and preparation of food material for long time taking benefit of the low pH and the action of products generated during the fermentative activity thereof.
  • Lactic acid bacteria are involved in the production of a variety of different food products, such as cheese or yogurt.
  • lactic acid bacteria in particular Lactobacilli and Bifidobacteria
  • probiotics have been found to be capable to survive the severe environmental conditions prevailing in the gastric tract and be able to at least transiently colonize the intestinal mucosa, where they bring about positive effects for the living beings having incorporated them.
  • EP 0 577 903 reference is made to the use of a lactic acid bacteria having the ability of replacing Heliobacter pylori, the acknowledged cause for the development of ulcer.
  • Lactobacillus GG ATCC 53103
  • the microorganism may be employed for preventing or treating food induced hypersensitivity reactions.
  • these probiotic strains may provide, there is a desire for obtaining more detailed information about the biology of these strains, especially about the interaction with the hosts, the phenomena of surviving different environmental conditions in the gut as well as about the capability to adhere to the intestine's mucosa. In particular the involvement thereof in the enhancement of the immune system and defense against pathogens is of high interest.
  • a problem of the present invention is to provide data about bacterial strains that exhibit properties beneficial for man and/or animals and occasionally elucidate.
  • the present invention provides for a nucleic acid as identified by SEQ ID. NO. 1 or parts or variants thereof coding for a functional polypeptide, which variants have a homology to the SEQ ID. No, 1 of about 75 %, preferably 80 %, more preferably 85 %, even more preferably 90 % even more preferred 95 %,
  • the present invention also pertains to a polypeptide as identified by SEQ LD, NO. 2 or functional parts or variants thereof, which variants have a degree of homology to the said SEQ. ID. No. 2 of about 75 %, preferably 80 %, more preferably 85 %, even more preferably 90 % even more preferred 95 %.
  • Serine proteinase inhibitors comprise a diverse group of proteins that form a super- family including more than 100 members. The majority of Serpins act as protease inhibitors and are involved in the regulation of several proteinase-activated physiological processes, important for the individual, such as blood clotting, complement mediated lysis, the immune response, glomeralonephritis.
  • Serpins examples include, ⁇ l-antitrypsin, antithrombin III, plasminogen activator inhibitor 1 (PAI-1) or plasminogen activator inhibitor 2.
  • the Serpins known so far have been the subject of intensive Research and they all seem to have a common characteristic loop, termed the reactive site loop (RSL), extending from the surface of the molecule containing the recognition sequence for the active site of the cognate serine protease.
  • RSL reactive site loop
  • the specificity of each inhibitor is considered to be determined primarily by the identity of the amino acid that is immediately amino-terminal to the site of potential cleavage of the inhibitor by the serine protease.
  • This amino acid known as the Pi site residue, is considered to form an acyl bond with the serine in the active site of the serine protease.
  • Serpins seem to act as "suicide inhibitors" forming a 1 : 1 stochiometric complex with the target proteinase, thus blocking their activity, According to recent data it has been indicated that the inhibitor is cleaved in the reactive center and that the complex is most likely trapped as a covalent acyl-enzyme complex.
  • Se ⁇ ins are involved in sophisticated biological processes such as modulating the immune system or inflammatory reactions or even remodelling the extracellular matrix of a higher living being their presence in procaryotes has not been expected. In fact, no Serpin has so far been reported to be derived from procaryotic cells. The present inventors are therefore the first to have found that also some bacterial cells may contain Serpins. Without wishing to be bound by any theory it is presently assumed that the probiotic properties, such as modulation of the immune system or the known property of the Bifidobacterial strain, from which it has been derived, may at least in part be due to the presence of the present Serpin.
  • nucleic acid according to the present invention shall designate a polynucleotide as identified by SEQ. ID. NO. 1 or parts or variants thereof, that yield a functional polypeptide.
  • the nucleic acid shown in SEQ ID NO. 1 may be truncated at its ends to an extent, at which the resulting polypeptide still yields the biological function.
  • the nucleic acid may also be modified by deleting, adding or replacing one or more nucleotides, with the proviso that the resulting polypeptide still exerts its biological function.
  • polypeptide according to the present invention shall designate a polypeptide as identified by SEQ. ID. NO. 2 or parts or variants thereof, that are functional. Therefore, the polypeptide of SEQ. ID. NO. 2 may be truncated at its ends to an extent, at which the polypeptide still yields the biological function. Likewise, the polypeptide may also be modified by having one or more amino acids being deleted, added or replaced, with the proviso that the resulting polypeptide still exerts its biological function.
  • the above mentioned nucleic acid may be inserted in a suitable host cell and expressed therein.
  • a nucleic acid according to the present in- vention may be inserted in a suitable vector, which allows propagation and/or expression in the desired host cell and inserted therein.
  • the vector will contain a marker gene to enable a stable propagation.
  • nucleic acid according to the present invention may also be included into the genome of the host, using the phenomenon of homologous recombination or other techniques, allowing insertion of a nucleic acid only into the host's chromosome.
  • a technique is e.g. described in EP 93 105 303J, the contents thereof is incorporated herein by way of reference.
  • the nucleic acid according to the present invention may be put under the control of an endogeneous or exogeneous regulon, e.g. a promotor, depending on whether the gene product shall be over-expressed, i.e. for collecting and purifying the polypeptide, or expressed to a certain extent to be delivered to an individual via a carrier system, such as a micro-organism.
  • the regulon e.g. the promoter, is preferably regulatable and/or inducible and will be operably linked with the coding molecule via any of the well-recognized and easily-practised methodologies for so doing,
  • recombinant constructs are then introduced for expression into suitable host cells such as, e.g., E. coli, Lactobacilli, Streptococci or Bifidobacteria as a prokaryotic host cell or Saccharomyces cerevisiae, insect cells, CHO or COS cells as eukaryotic host cells and the transformed or transduced host cells are cultured under conditions which allow expression of the heterologous gene.
  • suitable host cells such as, e.g., E. coli, Lactobacilli, Streptococci or Bifidobacteria as a prokaryotic host cell or Saccharomyces cerevisiae
  • insect cells CHO or COS cells as eukaryotic host cells
  • the transformed or transduced host cells are cultured under conditions which allow expression of the heterologous gene.
  • the gene product of the present polynucleotide will be subject to glycosylation upon expression in an eucaryotic expression system.
  • the present invention also comprises recombinant microorganisms containing at least a copy of the nucleic acid according to the present invention.
  • the nucleic acid may be included in a micro-organism, that is used to deliver the target- substance to the individual.
  • probiotic bacteria are suitable, since they are able to pass the gastric tract of an individual and get at least transiently implanted into the mucosa of a host. At this location it will exert its biological function as is seen in the present probiotic strain BL29, from which it was derived, Without wishing to be bound by any theory it is presently thought that the gene product of the present nucleic acid is involved in the anti- inflammatory activity displayed by the Bifidobacterial strain BL29.
  • any bacterial strain already including a nucleic acid according to the present invention may be used as a host cell, into which additional copies of the target nucleic acid may be included.
  • the host cell will express the gene product of a nucleic acid according to the present invention. Therefore, the host cells may be utilized for the synthesis of a polypeptide according to the present invention on large scale.
  • a "host cell" according to the present invention may be obtained by recombinant means, in that a nucleic acid according to the present invention is inserted in a suitable cell.
  • the Bifidobacteria itself may be subjected to common techniques of mutation of selection such that a strain having an increased amount of the corresponding gene product is
  • the isolation of the protein can be carried out according to known methods from the host cell or from the culture supernatant of the host cell. Such methods are described for example by Ausubel I., Frederick M., Current Protocols in Mol. Biol. (1992), John Wiley and Sons, New 5 York.
  • the polypeptide can be purified after recombinant production by affinity chromatography using known protein purification techniques, including immunoprecipita- tion, gel filtration, ion exchange chromatography, chromatofocussing, isoelec ric focussing, selective precipitation, electrophoresis, or the like,
  • the invention further comprises a method for detecting a nucleic acid or a polypeptide according to the present invention, comprising incubating a sample, e.g. cell lysates or a reverse transcript of an RNA sample, with either a nucleic acid molecule according to the invention and determining hybridization under stringent conditions of said nucleic acid molecule to a target nucleic acid molecule for determination of presence of a nucleic acid
  • a sample e.g. cell lysates or a reverse transcript of an RNA sample
  • a quantitative detection of the gene may be performed by PCR techniques, preferably by the use of quantitative RT-PCR using, e.g., the LightCycler TM of Roche Diagnostics GmbH, DE.
  • the present nucleic acid and/or polynucleotide may likewise be utilized for searching for additional strains exhibiting probiotic activities.
  • the approximate amount of hybridization of the nucleic acid with the target nucleic acid or nucleic acids of the bacterial strain is determined.
  • the approximate amount of hybridization may easily be determined qualitatively by e.g. visual inspection upon detecting hybridization. For example, if a gel is used to resolve labelled nucleic acid which hybridizes to target nucleic acid in the sample, the resulting band can be inspected visually.
  • FACS FACS may be utilized for a quantitative measurement,
  • nucleic acid or a polypeptide according to the present invention may be utilized for the identification, characterization and/or purification of molecules affecting biological process associated with the activity of serine proteases
  • Exemplary biological processes, in which serine proteases are involved comprise blood coagulation, fibrinolysis, immune reactions, complement activation, inflammatory responses extracellular matrix turnover, cell migration and prohormone activation, cancer metastasis,
  • nucleic acid or polypeptide according to the present invention may also be used for the development of molecules eventually suitable in the treatment and/or diagnosis of disease states, which involve the activity of serine proteases.
  • agonists or antagonists to the proteases but likewise agonists or antagonists to Serpins may be devised.
  • non-limiting examples for disease states considered by the present invention are improper blood coagulation, improper fibrinolysis, immune reactions, complement activation, inflammatory responses extracellular matrix turnover, cell migration and prohormone activation, cancer metastasis.
  • the use of various model systems or structural studies will enable the development of specific agonists and antagonists useful in regulating the function of the present Serpin and the proteases to which it binds. It may be envisaged that these can be peptides, mutated ligands, antibodies or other molecules able to interact with the present Serpin.
  • the nucleic acid according to the present invention may in general be utilized for the synthesis of the polypeptide for large scale production thereof, by expressing a nucleic acid according to the present invention or a vector containing such a nucleic acid in a suitable host under conditions suitable for the expression of the polypeptide and collecting and purifying the polypeptide.
  • Protein and/or nucleic acid sequence homologies have be evaluated using the following algorithms:
  • BLASTN Compares a nucleotide query sequence against a nucleotide sequence database
  • BLASTX Compares a nucleotide query sequence translated in all reading frames against a protein sequence database
  • TBLASTN Compares a protein query sequence against a nucleotide sequence database dynamically translated in all reading frames
  • the nucleic acid encoding the putative Bifidobacterial Serpin deleted from its signal peptide was cloned into the E. coli expression vector pDEST 17 (Invitrogen Life Technologies) and the corresponding protein was produced as a 6-His tagged fusion protein in E. coli (Janknecht R et al. (1991) : Proc. Natl. Acad. Sci. USA:88(20) pp 8972-8976) according to common techniques.
  • the 6-His tagged protein was purified to homogeneity by metal affinity chromatography on a nickel-nitrilotriacetic acid matrix (Ni-NTA from Quiagen) according to the instructions described in the QLA-Expressionist Handbook from Quiagen, and used for production of functional studies as well as for production of polyclonal antibodies in rabbits.
  • Ni-NTA nickel-nitrilotriacetic acid matrix
  • polypeptide as isolated in example 2 has been used in a haemolytic assay in vitro in order to deten ine its activity as a Serpin.
  • Bifidobacterium Serpin activity was compared to human serpin ⁇ l-antitrypsin (5 ⁇ g/well). Distilled water was used as positive control to obtain 100% erythrocyte lysis and human inactivated AB serum as negative control (no lysis due to complement inactivation).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)

Abstract

The present invention pertains to a novel gene of Bifidobacteria and to the polypeptides encoded thereby. In particular, the present invention pertains to a gene belonging to the Serpin superfamily and its use in the production of bacterial Serpins. Also provides are vectors host cells, and methods for producing bacterial Serpin polynucleotides and/or polypeptides.

Description

A Serpin in Bifidobacteria
The present invention pertains to a novel gene of Bifidobacteria and to the polypeptides encoded thereby. In particular, the present invention pertains to a gene belonging to the Serpin superfamily and its use in the production of bacterial Serpins. Also provided are vectors, host cells, and methods for producing bacterial Serpin polynucleotides and/or polypeptides.
Lactic acid bacteria have been utilized for the preservation and preparation of food material for long time taking benefit of the low pH and the action of products generated during the fermentative activity thereof. In addition, Lactic acid bacteria are involved in the production of a variety of different food products, such as cheese or yogurt.
Quite recently lactic acid bacteria, in particular Lactobacilli and Bifidobacteria, have attracted a great deal of attention in that some strains have been found to exhibit valuable properties to man and animals upon ingestion. These strains, which are generically designated probiotics, have been found to be capable to survive the severe environmental conditions prevailing in the gastric tract and be able to at least transiently colonize the intestinal mucosa, where they bring about positive effects for the living beings having incorporated them.
In EP 0 768 375 such a probiotic strain of the genus Bifidobacterium is disclosed, which is capable to become implanted in the intestinal flora. This Bifidobacterium is reported to assist in the immuno-modulation of the host, being able to competitively exclude adhesion of pathogenic bacteria to intestinal cells, thus supporting the maintenance of the individual's health.
Further, in EP 0 577 903 reference is made to the use of a lactic acid bacteria having the ability of replacing Heliobacter pylori, the acknowledged cause for the development of ulcer.
Also, in WO 97/00078 a specific lactobacillus strain, termed Lactobacillus GG (ATCC 53103), is disclosed as such a probiotic. The microorganism may be employed for preventing or treating food induced hypersensitivity reactions.
In view of the valuable properties these probiotic strains may provide, there is a desire for obtaining more detailed information about the biology of these strains, especially about the interaction with the hosts, the phenomena of surviving different environmental conditions in the gut as well as about the capability to adhere to the intestine's mucosa. In particular the involvement thereof in the enhancement of the immune system and defense against pathogens is of high interest.
Consequently, a problem of the present invention is to provide data about bacterial strains that exhibit properties beneficial for man and/or animals and occasionally elucidate.
In the line of investigating the genome of the probiotic Bifidobacterium strain BL29 the present inventors have surprisingly found a gene that shows a moderate homology to genes belonging to the Serpin superfamily (SERine Protease mhibitors). Genes for such type of genes have so far only been found in cells of higher organisms, such as humans and plants, but not in bacterial cells.
In consequence, the present invention provides for a nucleic acid as identified by SEQ ID. NO. 1 or parts or variants thereof coding for a functional polypeptide, which variants have a homology to the SEQ ID. No, 1 of about 75 %, preferably 80 %, more preferably 85 %, even more preferably 90 % even more preferred 95 %,
According to an alternative embodiment the present invention also pertains to a polypeptide as identified by SEQ LD, NO. 2 or functional parts or variants thereof, which variants have a degree of homology to the said SEQ. ID. No. 2 of about 75 %, preferably 80 %, more preferably 85 %, even more preferably 90 % even more preferred 95 %. Serine proteinase inhibitors (Serpins) comprise a diverse group of proteins that form a super- family including more than 100 members. The majority of Serpins act as protease inhibitors and are involved in the regulation of several proteinase-activated physiological processes, important for the individual, such as blood clotting, complement mediated lysis, the immune response, glomeralonephritis. pain sensing, inflammation, pancreatitis, cancer, regulating fertilization, bacterial infection and viral maturation. Though the primary function of Serpins appears to be neutralizing serine proteinase activity, these polypeptides have also been found to play a role in extracellular matrix remodelling and cell migration.
Examples for Serpins include, αl-antitrypsin, antithrombin III, plasminogen activator inhibitor 1 (PAI-1) or plasminogen activator inhibitor 2.
The Serpins known so far have been the subject of intensive Research and they all seem to have a common characteristic loop, termed the reactive site loop (RSL), extending from the surface of the molecule containing the recognition sequence for the active site of the cognate serine protease. The specificity of each inhibitor is considered to be determined primarily by the identity of the amino acid that is immediately amino-terminal to the site of potential cleavage of the inhibitor by the serine protease. This amino acid, known as the Pi site residue, is considered to form an acyl bond with the serine in the active site of the serine protease.
The Serpins seem to act as "suicide inhibitors" forming a 1 : 1 stochiometric complex with the target proteinase, thus blocking their activity, According to recent data it has been indicated that the inhibitor is cleaved in the reactive center and that the complex is most likely trapped as a covalent acyl-enzyme complex.
Since Seφins are involved in sophisticated biological processes such as modulating the immune system or inflammatory reactions or even remodelling the extracellular matrix of a higher living being their presence in procaryotes has not been expected. In fact, no Serpin has so far been reported to be derived from procaryotic cells. The present inventors are therefore the first to have found that also some bacterial cells may contain Serpins. Without wishing to be bound by any theory it is presently assumed that the probiotic properties, such as modulation of the immune system or the known property of the Bifidobacterial strain, from which it has been derived, may at least in part be due to the presence of the present Serpin.
In the context of this application a nucleic acid according to the present invention shall designate a polynucleotide as identified by SEQ. ID. NO. 1 or parts or variants thereof, that yield a functional polypeptide. To this end, the nucleic acid shown in SEQ ID NO. 1 may be truncated at its ends to an extent, at which the resulting polypeptide still yields the biological function. Likewise, the nucleic acid may also be modified by deleting, adding or replacing one or more nucleotides, with the proviso that the resulting polypeptide still exerts its biological function.
Similarly, the same applies to the polypeptide described herein. The term polypeptide according to the present invention shall designate a polypeptide as identified by SEQ. ID. NO. 2 or parts or variants thereof, that are functional. Therefore, the polypeptide of SEQ. ID. NO. 2 may be truncated at its ends to an extent, at which the polypeptide still yields the biological function. Likewise, the polypeptide may also be modified by having one or more amino acids being deleted, added or replaced, with the proviso that the resulting polypeptide still exerts its biological function.
According to an embodiment, the above mentioned nucleic acid may be inserted in a suitable host cell and expressed therein. For this purpose, a nucleic acid according to the present in- vention may be inserted in a suitable vector, which allows propagation and/or expression in the desired host cell and inserted therein. The vector will contain a marker gene to enable a stable propagation.
Likewise, the nucleic acid according to the present invention may also be included into the genome of the host, using the phenomenon of homologous recombination or other techniques, allowing insertion of a nucleic acid only into the host's chromosome. Such a technique is e.g. described in EP 93 105 303J, the contents thereof is incorporated herein by way of reference.
The nucleic acid according to the present invention may be put under the control of an endogeneous or exogeneous regulon, e.g. a promotor, depending on whether the gene product shall be over-expressed, i.e. for collecting and purifying the polypeptide, or expressed to a certain extent to be delivered to an individual via a carrier system, such as a micro-organism. The regulon, e.g. the promoter, is preferably regulatable and/or inducible and will be operably linked with the coding molecule via any of the well-recognized and easily-practised methodologies for so doing,
These recombinant constructs are then introduced for expression into suitable host cells such as, e.g., E. coli, Lactobacilli, Streptococci or Bifidobacteria as a prokaryotic host cell or Saccharomyces cerevisiae, insect cells, CHO or COS cells as eukaryotic host cells and the transformed or transduced host cells are cultured under conditions which allow expression of the heterologous gene. It will be appreciated that the gene product of the present polynucleotide will be subject to glycosylation upon expression in an eucaryotic expression system.
According to another aspect the present invention also comprises recombinant microorganisms containing at least a copy of the nucleic acid according to the present invention. The nucleic acid may be included in a micro-organism, that is used to deliver the target- substance to the individual. In this respect probiotic bacteria are suitable, since they are able to pass the gastric tract of an individual and get at least transiently implanted into the mucosa of a host. At this location it will exert its biological function as is seen in the present probiotic strain BL29, from which it was derived, Without wishing to be bound by any theory it is presently thought that the gene product of the present nucleic acid is involved in the anti- inflammatory activity displayed by the Bifidobacterial strain BL29. Likewise, any bacterial strain, already including a nucleic acid according to the present invention may be used as a host cell, into which additional copies of the target nucleic acid may be included. The host cell will express the gene product of a nucleic acid according to the present invention. Therefore, the host cells may be utilized for the synthesis of a polypeptide according to the present invention on large scale.
5 A "host cell" according to the present invention may be obtained by recombinant means, in that a nucleic acid according to the present invention is inserted in a suitable cell. However, in order to increase the amount of Bifido-Serpin in the Bifidobacteria containing such sort of polypeptides, the Bifidobacteria itself may be subjected to common techniques of mutation of selection such that a strain having an increased amount of the corresponding gene product is
0 obtained.
The isolation of the protein can be carried out according to known methods from the host cell or from the culture supernatant of the host cell. Such methods are described for example by Ausubel I., Frederick M., Current Protocols in Mol. Biol. (1992), John Wiley and Sons, New 5 York. The polypeptide can be purified after recombinant production by affinity chromatography using known protein purification techniques, including immunoprecipita- tion, gel filtration, ion exchange chromatography, chromatofocussing, isoelec ric focussing, selective precipitation, electrophoresis, or the like,
:0 The invention further comprises a method for detecting a nucleic acid or a polypeptide according to the present invention, comprising incubating a sample, e.g. cell lysates or a reverse transcript of an RNA sample, with either a nucleic acid molecule according to the invention and determining hybridization under stringent conditions of said nucleic acid molecule to a target nucleic acid molecule for determination of presence of a nucleic acid
'.5 molecule, or using antibodies, preferably monoclonal antibodies raised against the polypeptide according to the present invention. Also a quantitative detection of the gene may be performed by PCR techniques, preferably by the use of quantitative RT-PCR using, e.g., the LightCycler TM of Roche Diagnostics GmbH, DE.
>0 Since the Serpin gene seems to be associated with probiotic activity of bacterial strains, the present nucleic acid and/or polynucleotide may likewise be utilized for searching for additional strains exhibiting probiotic activities.
To determine, whether a given bacterial strain may be apt, the approximate amount of hybridization of the nucleic acid with the target nucleic acid or nucleic acids of the bacterial strain is determined. The approximate amount of hybridization may easily be determined qualitatively by e.g. visual inspection upon detecting hybridization. For example, if a gel is used to resolve labelled nucleic acid which hybridizes to target nucleic acid in the sample, the resulting band can be inspected visually. Likewise, as with the use of antibodies FACS may be utilized for a quantitative measurement,
The nucleic acid or a polypeptide according to the present invention may be utilized for the identification, characterization and/or purification of molecules affecting biological process associated with the activity of serine proteases, Exemplary biological processes, in which serine proteases are involved comprise blood coagulation, fibrinolysis, immune reactions, complement activation, inflammatory responses extracellular matrix turnover, cell migration and prohormone activation, cancer metastasis,
Likewise, the nucleic acid or polypeptide according to the present invention may also be used for the development of molecules eventually suitable in the treatment and/or diagnosis of disease states, which involve the activity of serine proteases. Once the interaction of the present Serpin with the target proteases has been understood, agonists or antagonists to the proteases, but likewise agonists or antagonists to Serpins may be devised. As mentioned above, non-limiting examples for disease states considered by the present invention are improper blood coagulation, improper fibrinolysis, immune reactions, complement activation, inflammatory responses extracellular matrix turnover, cell migration and prohormone activation, cancer metastasis.
The use of various model systems or structural studies will enable the development of specific agonists and antagonists useful in regulating the function of the present Serpin and the proteases to which it binds. It may be envisaged that these can be peptides, mutated ligands, antibodies or other molecules able to interact with the present Serpin. The nucleic acid according to the present invention may in general be utilized for the synthesis of the polypeptide for large scale production thereof, by expressing a nucleic acid according to the present invention or a vector containing such a nucleic acid in a suitable host under conditions suitable for the expression of the polypeptide and collecting and purifying the polypeptide.
The following examples illustrate the invention without limiting it thereto.
Example 1
Isolation of the Serpin gene
In the line of sequencing the genome of the Bifidobacterium longum strain BL29 by the method of directed sequencing after fluorescent automated sequencing of the inserts of clones and assembling of these sequences of nucleotide fragments (inserts) by means of software programmes, an open reading frame has been found, To achieve that, fragments of the genome were created, ligated into suitable vectors for amplification and propagation and the corresponding fragments have been sequenced. Overlaps and the final arrangement of the fragments, the nucleotide sequence thereof, were assessed by the aid of appropriate soft- wares.
Protein and/or nucleic acid sequence homologies have be evaluated using the following algorithms:
(1) BLASTP: Compares an amino acid query sequence against a protein sequence database
(2) BLASTN: Compares a nucleotide query sequence against a nucleotide sequence database
(3) BLASTX: Compares a nucleotide query sequence translated in all reading frames against a protein sequence database (4) TBLASTN: Compares a protein query sequence against a nucleotide sequence database dynamically translated in all reading frames
A modest overall homology to the known murine Serpin α-2-antiρlasmin of about 43 % has been noted. Yet the present polypeptide shows a homology of about 63 % with the reactive site loop (RSL) thereof.
Example 2
Cloning of the Bifidobacterial Serpin gene and isolation of the polypeptide
The nucleic acid encoding the putative Bifidobacterial Serpin deleted from its signal peptide, was cloned into the E. coli expression vector pDEST 17 (Invitrogen Life Technologies) and the corresponding protein was produced as a 6-His tagged fusion protein in E. coli (Janknecht R et al. (1991) : Proc. Natl. Acad. Sci. USA:88(20) pp 8972-8976) according to common techniques.
The 6-His tagged protein was purified to homogeneity by metal affinity chromatography on a nickel-nitrilotriacetic acid matrix (Ni-NTA from Quiagen) according to the instructions described in the QLA-Expressionist Handbook from Quiagen, and used for production of functional studies as well as for production of polyclonal antibodies in rabbits.
Example 3
Potential anti-inflammatory activity of a serpin-like protein, expressed in BL29
The polypeptide as isolated in example 2 has been used in a haemolytic assay in vitro in order to deten ine its activity as a Serpin.
To this end, 50 μl of successive doubling dilution of human AB serum (Sigma) were mixed in a 96 microtiter well plate with 50 μl of a 1 J % sheep antibody-activated sheep erythrocyte suspension. To assess anti-haemolytic activity of the recombinant Serpin, 1 μg of the recombinant protein was added to each well and the mixture was incubated for 1 hr at 7°C. The plate was then centrifuged to pellet intact cells and cell debris and the supernatant was transferred to a new plate. Haemolytic activity was estimated by measuring haemoglobin release as absorbance at 450 nm.
Bifidobacterium Serpin activity was compared to human serpin αl-antitrypsin (5 μg/well). Distilled water was used as positive control to obtain 100% erythrocyte lysis and human inactivated AB serum as negative control (no lysis due to complement inactivation).
The results clearly indicate that recombinant Serpin from Bifidobacteria inhibited human red blood cell lysis to a similar extent as human αl-antitrypsin, a known serine-protease inhibitor,

Claims

Claims
1. A nucleic acid as identified by SEQ ID. NO. 1 or parts or variants thereof coding for a 5 functional polypeptide, which variants have a homology to the SEQ LD. No. 1 of about 75 %, preferably 80 %, more preferably 85 %, even more preferably 90 % even more preferred 95 %.
2. A polypeptide as identified by SEQ ID. NO. 2 or functional parts or variants thereof, i 0 that have a degree of homology to the said SEQ. ID. No. 2 of about 75 %, preferably
80 %, more preferably 85 %, even more preferably 90 % even more preferred 95 %.
3. A vector containing a nucleic acid according to claim 1.
5 4. A host cell containing one or more copies of a nucleic acid according to claim 1 or a vector according to claim 3.
5. A host cell according to claim 4, wherein a polypeptide according to claim 2 is expressed.
!0
6. Use of a nucleic acid or a polypeptide according to any of the claims 1 or 2 for the identification, characterization and/or purification of molecules affecting a biological process associated with the activity of serine proteases.
;5 7. Use of a nucleic acid or a polypeptide according to any of the claims 1 or 2 for the development of molecules for the treatment and diagnosis of disease states, involving the activity of serine proteases.
8. Use of a nucleic acid according to claim 1 or a polypeptide according to claim 2, for O the preparation of a carrier for the treatment and/or prevention of disease states involving the activity of serine proteases.
9. The use according to claim 8, wherein the carrier is a medicament, a food product or a food supplement.
10. The use according to any of the claims 6 to 9, wherein the biological process or the 5 disease states are selected from the group consisting of blood coagulation, fibrinolysis, immune reactions, complement activation, inflammatory responses extracellular matrix turnover, cell migration and prohormone activation, cancer metastasis.
11. A method of producing a polypeptide according to claim 2, which comprises 10 expressing a nucleic acid according to claim 1 or a vector according to claim 3 in a suitable host and purifying the polypeptide obtained.
12. A method for detecting probiotic strains, which comprises screening micro-organisms with a nucleic acid according to claim 1 or an antibody directed to a polypeptide
15 according to claim 2, for the presence of the said nucleic acid or the said polypeptide and determining the presence of a Serpin in the micro-organisms.
13. A method for producing a micro-organism expressing or over-expressing the Serpin encoded by a nucleic acid according to claim 1, which comprises, transforming a 0 micro-organism with a nucleic acid according to claim 1 and expressing the gene encoding the Serpin polypeptide.
14. A food or pharmaceutical product, containing a nucleic acid according to claim 1, a polypeptide according to claim 2, a vector according to claim 3 or a host cell
'5 according to any of the claims 4 or 5.
PCT/EP2002/000956 2001-01-30 2002-01-30 A serpin in bifidobacteria Ceased WO2002060932A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002561500A JP4249483B2 (en) 2001-01-30 2002-01-30 Serpins in bifidobacteria
AU2002249151A AU2002249151A1 (en) 2001-01-30 2002-01-30 A serpin in bifidobacteria
EP02718062A EP1358332B1 (en) 2001-01-30 2002-01-30 A serpin in bifidobacteria
DE60215461T DE60215461T2 (en) 2001-01-30 2002-01-30 SERPIN OF BIFIDOBAKTERIA
US10/470,559 US7700315B2 (en) 2001-01-30 2002-01-30 Serpin in bifidobacteria
CA2436049A CA2436049C (en) 2001-01-30 2002-01-30 A serpin in bifidobacteria

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01102050.0 2001-01-30
EP01102050A EP1227152A1 (en) 2001-01-30 2001-01-30 Bacterial strain and genome of bifidobacterium

Publications (2)

Publication Number Publication Date
WO2002060932A2 true WO2002060932A2 (en) 2002-08-08
WO2002060932A3 WO2002060932A3 (en) 2003-06-05

Family

ID=8176339

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP2002/000956 Ceased WO2002060932A2 (en) 2001-01-30 2002-01-30 A serpin in bifidobacteria
PCT/EP2002/000955 Ceased WO2002060931A2 (en) 2001-01-30 2002-01-30 A fimbria-like gene in bifidobacteria
PCT/EP2002/000958 Ceased WO2002074798A2 (en) 2001-01-30 2002-01-30 The genome of a bifidobacterium

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/EP2002/000955 Ceased WO2002060931A2 (en) 2001-01-30 2002-01-30 A fimbria-like gene in bifidobacteria
PCT/EP2002/000958 Ceased WO2002074798A2 (en) 2001-01-30 2002-01-30 The genome of a bifidobacterium

Country Status (12)

Country Link
US (2) US7183101B2 (en)
EP (3) EP1227152A1 (en)
JP (2) JP4570329B2 (en)
CN (3) CN101671640B (en)
AT (1) ATE342986T1 (en)
AU (3) AU2002247668A1 (en)
CA (2) CA2436049C (en)
DE (1) DE60215461T2 (en)
DK (1) DK1358332T3 (en)
ES (2) ES2274019T3 (en)
PT (2) PT1360299E (en)
WO (3) WO2002060932A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101880668A (en) * 2010-05-07 2010-11-10 广西大学 A gene encoding a serine protease inhibitor and its application
CN105694892A (en) * 2016-03-16 2016-06-22 山东大学 Preparation method of CdSe quantum dot with surface carrying positive charges

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271781B2 (en) 2000-03-03 2007-09-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiplex hybridization system for identification of pathogenic mycobacterium and method of use
EP1227152A1 (en) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
EP1264893A1 (en) 2001-06-08 2002-12-11 Teagasc Dairy Products Research Centre CLA biosynthesis by bifidobacteria
WO2003048351A1 (en) 2001-12-03 2003-06-12 Kyowa Hakko Kogyo Co., Ltd. Mutated 6-phosphogluconate dehydrogenase
CN100532557C (en) 2002-08-23 2009-08-26 纳幕尔杜邦公司 Use of starch products in biological production by fermentation
AU2004235346A1 (en) 2003-04-25 2004-11-11 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
DE602004032144D1 (en) 2003-06-23 2011-05-19 Univ North Carolina State LACTOBACILLUS ACIDOPHILUS NUCLEIC ACIDS CODING FOR FRUCTOOLIGOSACCHARIDE-USING COMPOUNDS AND USES THEREOF
WO2005000882A2 (en) * 2003-06-27 2005-01-06 University College Cork - National University Of Ireland, Cork Dna fragments and proteins encoded by said dna isolated from bifidobacteria
ATE360682T1 (en) 2003-06-30 2007-05-15 Clasado Inc NEW GALACTOOLIGOSACCHARIDE COMPOSITION AND PRODUCTION THEREOF
KR100492455B1 (en) * 2003-09-26 2005-05-30 주식회사 비피도 Bifidobacterium longum AR81 enabling inhibition of rotavirus and active protein separated therefrom
WO2005034971A2 (en) * 2003-10-08 2005-04-21 Masami Moriyama Antiviral agent
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7455992B2 (en) 2004-02-23 2008-11-25 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding protease homologues and uses therefore
WO2005085478A2 (en) * 2004-02-27 2005-09-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Detection and identification of mycobacterium and nocardia using primers and probes directed to the seca1 gene
US7608700B2 (en) 2004-03-08 2009-10-27 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding stress-related proteins and uses therefor
US7459289B2 (en) 2004-03-08 2008-12-02 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor
US7550576B2 (en) 2004-08-09 2009-06-23 North Carolina State University Nucleic acid sequences encoding two-component sensing and regulatory proteins, antimicrobial proteins and uses therefor
JP4784224B2 (en) * 2004-09-24 2011-10-05 味の素株式会社 Glycosyl transfer method and glycosyltransferase
EP1814995A2 (en) 2004-10-27 2007-08-08 North Carolina State University Lactobacillus acidophilus nucleic acids and uses thereof
US7495092B2 (en) 2005-01-14 2009-02-24 North Carolina State University Compositions comprising promoter sequences and methods of use
EP1856148B8 (en) 2005-03-07 2013-04-10 Barbara Kofler Neuropeptides
ES2325887T3 (en) * 2005-05-16 2009-09-23 Universite De Liege PROBIOTIC BIFIDOBACTERIAL SPECIES.
ATE512211T1 (en) 2005-05-31 2011-06-15 Iams Company FELINE PROBIOTIC LACTOBACILLI
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
GB0525857D0 (en) 2005-12-20 2006-02-01 Product and process
GB0601901D0 (en) 2006-01-31 2006-03-08 Product and Process
GB0606112D0 (en) 2006-03-28 2006-05-03 Product and process
CN100389125C (en) * 2006-05-30 2008-05-21 中国科学院昆明动物研究所 Rana grahami propyl sperm peptide, gene and variant and its pharmaceutical use
EP2124966B1 (en) 2007-02-01 2015-09-09 IAMS Europe B.V. Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts
CN101273738B (en) * 2007-03-28 2011-06-01 哈尔滨正方科技有限公司 Method for preparing recombined sour milk drinks having higher viable bacteria at normal temperature
EP2522358B1 (en) * 2007-06-27 2016-11-09 Laboratorios Ordesa, S.l. Peptides against rotavirus infection
EP2053122A1 (en) * 2007-10-23 2009-04-29 Nestec S.A. Stress tolerant bifidobacteria
US9730968B2 (en) 2008-04-17 2017-08-15 Anaeropharma Science, Inc. Therapeutic agent for ischemic diseases
CN101570755B (en) * 2008-04-29 2011-09-28 中国农业科学院植物保护研究所 Novel gene of virus original protease inhibitor as well as expression and application thereof
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
MX356598B (en) 2008-11-11 2018-06-04 Alimentary Health Ltd Bifidobacterium longum.
US8784798B2 (en) * 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
AU2009347008B2 (en) 2009-05-27 2013-08-15 Clasado Limited Method of preventing diarrhoea
EP2270134A1 (en) * 2009-07-03 2011-01-05 Nestec S.A. Oxidative stress resistant Bifidobacteria
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
ES2664724T3 (en) * 2009-08-18 2018-04-23 Nestec S.A. Nutritional composition comprising strains of Bifidobacterium longum and reducing symptoms of food allergy, especially in infants and children
JPWO2011027875A1 (en) * 2009-09-03 2013-02-04 独立行政法人理化学研究所 Intestinal barrier function improver
ES2610829T3 (en) * 2009-11-11 2017-05-03 Alimentary Health Limited Bifidobacterium strain
CA2786847C (en) * 2010-01-14 2017-08-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (ibd) and irritable bowel syndrome (ibs)
CA2787590C (en) * 2010-01-29 2019-01-15 Anaeropharma Science, Inc. Transforming plasmid
US8755425B2 (en) * 2010-06-30 2014-06-17 Comtech Ef Data Corp. Method and system for transmission of identification via metadata for repeating relays using spread-spectrum technology
EP2397145A1 (en) * 2010-06-18 2011-12-21 Nestec S.A. L. johnsonii La1, B. longum NCC2705 and immune disorders
CN101884782B (en) * 2010-06-29 2015-09-16 南昌大学 The application of bifidobacterium longum adhesion inhibition protein A ip in control diarrhoea
CN103025930B (en) 2010-07-02 2014-11-12 宝洁公司 Method for delivering an active agent
MX345025B (en) 2010-07-02 2017-01-12 Procter & Gamble Detergent product.
US20180163325A1 (en) 2016-12-09 2018-06-14 Robert Wayne Glenn, Jr. Dissolvable fibrous web structure article comprising active agents
BR112013000101A2 (en) 2010-07-02 2016-05-17 Procter & Gamble filaments comprising active agent nonwoven webs and methods of manufacture thereof
EP2449891A1 (en) * 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
GB201021399D0 (en) 2010-12-16 2011-01-26 Genetic Analysis As Oligonucleotide probe set and methods of microbiota profiling
TWI487530B (en) * 2011-01-10 2015-06-11 Produce high cell immunity reaction from isolated bifidobacterium longum subsp. longum
CA2832279C (en) * 2011-04-05 2024-03-05 Mascoma Corporation Methods for the improvement of product yield and production in a microorganism through the addition of alternate electron acceptors
CA2841451A1 (en) * 2011-07-13 2013-01-17 Anaeropharma Science, Inc. Ischemic disease therapeutic agent
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
RU2527069C2 (en) * 2011-11-08 2014-08-27 Автономная Некоммерческая Организация "Научно-исследовательский центр биотехнологи антибиотиков и других биологически активных веществ "БИОАН" METHOD OF SPECIES AND STRAIN IDENTIFICATION OF BIFIDOBACTERIA OF PHYLOTYPE Bifidobacterium longum
IN2014DN07752A (en) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
US8686114B2 (en) 2012-03-05 2014-04-01 E I Du Pont De Nemours And Company Variant sucrose transporter polypeptides
US9161957B2 (en) 2012-08-03 2015-10-20 Life Well Lived, Llc Compositions and methods for reducing blood alcohol content
DK2909334T3 (en) * 2012-10-17 2020-09-28 Enterome Gene signatures of inflammatory disorders related to liver and Crohn's disease
FR2999933B1 (en) * 2012-12-21 2020-01-31 Société des Produits Nestlé S.A. USE OF PROBIOTIC MICROORGANISMS AS A MELANIN SYNTHESIS AGENT
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP3033351A4 (en) 2013-08-12 2017-03-22 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules
US10443061B2 (en) 2014-05-01 2019-10-15 Anaeropharma Science, Inc. Heterologous polypeptide expression cassette
SG11201609108TA (en) 2014-05-02 2016-12-29 Univ Shinshu Antibody gene expression-secretion system
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
SG11201704450UA (en) 2014-12-03 2017-06-29 Anaeropharma Science Inc Coexpression plasmid
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
US20180267037A1 (en) * 2014-12-23 2018-09-20 Evolve Biosystems Inc. Method for the noninvasive detection of activated bifidobacteria
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
GB201508860D0 (en) 2015-05-22 2015-07-01 Nat Univ Ireland Diagnostic method
ME03511B (en) 2015-06-15 2020-04-20 4D Pharma Res Ltd COMPOSITIONS WITH BACTERIAL STRAINS
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
HRP20191949T1 (en) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis and wexlerae for use in treating inflammatory and autoimmune diseases
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
HK1254843B (en) 2015-11-20 2020-04-17 希杰生物科技株式会社 Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (en) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN106478812B (en) * 2016-10-21 2020-11-20 沈阳药科大学 Serine protease inhibitor-3 and its function, preparation method and application
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP6882519B2 (en) 2017-01-27 2021-06-02 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ Composition in the form of a soluble solid structure comprising effervescent agglomerated particles
MX380853B (en) 2017-01-27 2025-03-12 Procter & Gamble Compositions in the form of dissolvable solid structures
PT3609910T (en) 2017-04-11 2026-01-20 Kerry Group Services Int Ltd Lactase enzymes with improved properties
US12486305B2 (en) 2017-04-11 2025-12-02 Kerry Group Services International Ltd Lactase enzymes with improved properties
EP3609909B1 (en) 2017-04-11 2025-07-02 Kerry Group Services International Ltd Lactase enzymes with improved activity at low temperatures
US12435326B2 (en) 2017-04-11 2025-10-07 Kerry Group Services International Ltd Lactase enzymes with improved properties
WO2018213003A1 (en) 2017-05-16 2018-11-22 The Procter & Gamble Company Conditioning hair care compositions in the form of dissolvable solid structures
ES2877726T3 (en) 2017-05-22 2021-11-17 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
TWI812624B (en) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 Compositions comprising bacterial strains
PL3600363T3 (en) 2017-06-14 2021-06-14 4D Pharma Research Limited Compositions comprising bacterial strains
ES2841902T3 (en) 2017-06-14 2021-07-12 4D Pharma Res Ltd Compositions comprising bacterial strains
CN111372596A (en) 2017-08-30 2020-07-03 潘德勒姆治疗公司 Methods and compositions for treating microbiome-related disorders
WO2019055940A1 (en) * 2017-09-18 2019-03-21 Dupont Nutrition Biosciences Aps Riboflavinase enzymes and their use to prevent off flavor in brewing
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
US11666514B2 (en) 2018-09-21 2023-06-06 The Procter & Gamble Company Fibrous structures containing polymer matrix particles with perfume ingredients
JP2022504684A (en) * 2018-10-17 2022-01-13 セーホーエル．ハンセン アクティーゼルスカブ Lactose-degrading enzyme with improved properties at acidic pH
CN110343672B (en) * 2018-12-27 2021-07-06 华东理工大学 A carbamoyl phosphate synthase mutant resistant to uridylic acid feedback inhibition and its application
JP2021083433A (en) * 2019-11-29 2021-06-03 地方独立行政法人神奈川県立産業技術総合研究所 Antigen-binding molecule, nucleic acid composition, vector composition and method for purifying cells and bifidobacterium longum
MX2023001042A (en) 2020-07-31 2023-02-16 Procter & Gamble Water-soluble fibrous pouch containing prills for hair care.
CN112458015B (en) * 2020-11-27 2021-11-19 石家庄君乐宝乳业有限公司 Bifidobacterium longum subspecies longum i772, and separation and purification method and application thereof
KR102314882B1 (en) * 2021-01-29 2021-10-19 씨제이제일제당 (주) Novel membrane protein TerC variant and a method for producing L-lysine using the same
WO2023034763A1 (en) 2021-08-30 2023-03-09 The Procter & Gamble Company Dissolvable solid structure comprising first and second polymeric structurants
CN113957073B (en) * 2021-10-19 2023-09-01 山东寿光巨能金玉米开发有限公司 Tkt gene promoter mutant and application thereof in L-lysine production
MX2024005474A (en) 2021-12-17 2024-05-22 Procter & Gamble Dissolvable solid fibrous shampoo articles containing salts.
MX2024010903A (en) 2022-03-10 2024-09-17 Procter & Gamble Dissolvable solid structure having first and second layers.
CN114774335B (en) * 2022-06-22 2022-09-02 广东省科学院微生物研究所(广东省微生物分析检测中心) Bifidobacterium longum 070103 with effects of targeting glucokinase and remarkably reducing blood sugar and blood fat and application thereof
CN116334263B (en) * 2023-04-21 2025-03-25 四川农业大学 A dual PCR primer, kit and detection method for detecting pathogenic bacteria of fish gill nodule disease
CN116814822B (en) * 2023-08-25 2023-11-24 中国食品发酵工业研究院有限公司 Identification method and application of bifidobacterium longum subspecies infancy CICC 6069 strain
CN117551799B (en) * 2024-01-11 2024-03-19 广东海洋大学 Primer combination for nocardia seriolae strain typing, multiplex PCR identification method and application
CN118086539B (en) * 2024-03-05 2024-10-01 中国食品发酵工业研究院有限公司 PMA-qPCR Quantitative Detection Method for Live Bacteria of Bifidobacterium longum Subspecies Infantis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62195823U (en) * 1986-06-02 1987-12-12
JPH0687732B2 (en) * 1987-02-25 1994-11-09 カルピス食品工業株式会社 Method for producing fermented milk containing bifidobacteria
EP0768375B2 (en) * 1992-07-06 2002-06-12 Societe Des Produits Nestle S.A. Lactic bacteria
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
JP4469026B2 (en) * 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Streptococcus pneumoniae antigens and vaccines
CA2289116A1 (en) * 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
JP4046389B2 (en) * 1997-09-04 2008-02-13 株式会社ヤクルト本社 Bifidobacterium breve and fermented soymilk using the same
EP1227152A1 (en) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE SWALL [Online] EBI; Q9SDD0, 1 May 2000 (2000-05-01) SASAKI ET AL: "similar to serpin - wheat" retrieved from EBI Database accession no. Q9SDD0 XP002203432 *
HIROSHI M. ET AL: "Pathogenic mechanisms induced by microbial proteases in microbial infections" BIOLOGICAL CHEMISTRY HOPPE-SEYER, vol. 377, no. 4, 1996, pages 217-226, XP001084685 *
LETOFFE S. ET AL: "Characterization of a protein inhibitor of extracellular proteases produced by Erwinia chrysanthemi" MOECULAR MICROBIOLOGY, vol. 3, no. 1, January 1989 (1989-01), pages 79-86, XP001084689 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101880668A (en) * 2010-05-07 2010-11-10 广西大学 A gene encoding a serine protease inhibitor and its application
CN101880668B (en) * 2010-05-07 2012-05-23 广西大学 Gene for coding serpin and application thereof
CN105694892A (en) * 2016-03-16 2016-06-22 山东大学 Preparation method of CdSe quantum dot with surface carrying positive charges

Also Published As

Publication number Publication date
EP1358332A2 (en) 2003-11-05
AU2002247668A1 (en) 2002-08-12
EP1360299A2 (en) 2003-11-12
EP1227152A1 (en) 2002-07-31
DK1358332T3 (en) 2007-01-08
CN100516220C (en) 2009-07-22
ATE342986T1 (en) 2006-11-15
WO2002060931A3 (en) 2002-10-24
CN101671640A (en) 2010-03-17
CA2435664C (en) 2013-04-30
JP2004531245A (en) 2004-10-14
CN1500146A (en) 2004-05-26
WO2002074798A3 (en) 2002-12-12
JP4570329B2 (en) 2010-10-27
DE60215461D1 (en) 2006-11-30
US7183101B2 (en) 2007-02-27
EP1360299B1 (en) 2013-04-10
CN1518598A (en) 2004-08-04
WO2002060931A2 (en) 2002-08-08
JP2004531229A (en) 2004-10-14
JP4249483B2 (en) 2009-04-02
CA2435664A1 (en) 2002-09-26
EP1358332B1 (en) 2006-10-18
US20040115773A1 (en) 2004-06-17
AU2002302360A1 (en) 2002-10-03
CN100558896C (en) 2009-11-11
ES2420907T3 (en) 2013-08-27
AU2002249151A1 (en) 2002-08-12
CA2436049C (en) 2012-01-03
ES2274019T3 (en) 2007-05-16
US7700315B2 (en) 2010-04-20
US20040126870A1 (en) 2004-07-01
WO2002060932A3 (en) 2003-06-05
CA2436049A1 (en) 2002-08-08
PT1360299E (en) 2013-07-16
CN101671640B (en) 2012-08-22
DE60215461T2 (en) 2007-05-03
PT1358332E (en) 2007-01-31
WO2002074798A2 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
US7700315B2 (en) Serpin in bifidobacteria
Gilson et al. Evidence for high affinity binding‐protein dependent transport systems in gram‐positive bacteria and in Mycoplasma.
Peng et al. Purification and characterization of a fibrinolytic enzyme produced by Bacillus amyloliquefaciens DC-4 screened from douchi, a traditional Chinese soybean food
Benjelloun-Touimi et al. SepA, the 110 kDa protein secreted by Shigella flexneri: two-domain structure and proteolytic activity
CA2269636A1 (en) C3 binding protein of streptococcus pneumoniae
Chavagnat et al. Purification, characterization, gene cloning, sequencing, and overexpression of aminopeptidase N from Streptococcus thermophilus A
Dieckelmann et al. The diversity of lipases from psychrotrophic strains of Pseudomonas: a novel lipase from a highly lipolytic strain of Pseudomonas fluorescens
US20090214498A1 (en) Antimicrobial peptides and bacterial strains that produce them
JPH05505943A (en) Collagen binding protein and its production method
EP1227153A2 (en) Serpin from Bifidobacteria
Gunne et al. Efficient secretion of attacin from insect fat‐body cells requires proper processing of the prosequence
CA2247072A1 (en) Bacterial elastin binding protein, nucleic acid sequence encoding same and diagnostic and therapeutic methods of use thereof
JPH06505144A (en) A novel bacteriocin from Lactococcus lactis subspice cremoris
US20040058361A1 (en) Antibacterial treatments
CN115572329B (en) Poecilobdella manillensis gene recombinant hirudin with slower activity enhancement metabolism and preparation method thereof
Ali The Influence of Streptococcus pneumoniae Serine Proteases on Pneumococcal Pathogenesis
AU4396199A (en) Saccharide transporter
Aono Probable detection of Kil peptide derived from colicin E1 plasmid in the envelope fraction of Escherichia coli HB101 carrying pEAP31
AU2002216278A1 (en) Antibacterial treatments
Yamamoto et al. Maturation factor for the activation process of an extracellular proteinase in Lactobacillus helveticus CP790
RU2373281C2 (en) Method of producing recombinant staphylokinase with regulation of oxygen level
JP2002017357A (en) Anchor peptide, fusion protein, and protein immobilization method
JP2004097153A (en) Recombinant Bacillus megaterium
Berry A STUDY OF THE INSECTICIDAL TOXIN GENES OF BACILLUS SPHAERICUS, STRAINS 1593, 2362 AND 2297.
Poolman et al. Casein-breakdown by Lactococcus lactis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002718062

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2436049

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002561500

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 028043189

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002718062

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10470559

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002718062

Country of ref document: EP